Targeting CDK2 and other novel cell cycle targets for breast cancer therapy.

Abstract

Introduction: The dysregulation of cyclin-dependent kinases (CDKs) is a key driver of cancer progression, making them attractive therapeutic targets. In CDK4/6 inhibitor (CDK4/6i)-resistant breast cancer, targeting CDK2 offers a promising approach. CDK2 is frequently hyperactivated due to cyclin E1 overexpression or retinoblastoma protein loss, acting as a mechanism that sustains proliferation despite CDK4/6 inhibition. CDK2 inhibitors (CDK2i) show strong anti-tumor activity, particularly in combination with CDK4/6i or immune checkpoint inhibitors.

Areas covered: This review explores the biological roles of CDK2 and its regulatory mechanisms. The review highlights the latest advancements in CDK2i, their mechanisms of action, and their potential in combination strategies with CDK4/6i, chemotherapy, and immunotherapies. Additionally, it examines other emerging targets, such as CDK7 and CDK5, which contribute to transcriptional regulation and immune evasion, respectively.

Expert opinion: Future research should focus on biomarker-driven patient selection, optimizing CDK2i combinations, and expanding CDK7 inhibitor applications. Integrating multi-omics profiling can refine patient stratification, while combination strategies with chemotherapy, DNA damaging agents, and immunotherapies may enhance efficacy. CDK7 inhibitors could also complement CDK2 targeting by modulating resistance mechanisms. Personalized, adaptive treatment approaches will be key to maximizing the clinical impact of CDK2 and CDK7 inhibitors in breast cancer therapy.